MGMT promoter methylation status in newly diagnosed glioblastomas: Retrospective analysis from a clinical series of patients

13021 Background: Current standard treatment of newly diagnosed GBM is radiotherapy (RT) with concurrent Temozolomide (TMZ), followed by TMZ according to the EORTC/NCIC trial. MGMT promoter methylation status has been correlated with prolonged overall survival (OS) and survival benefit from treatment with TMZ and RT. The aim of our study is to assess the efficacy of this schedule in a cohort of patients (pts) out of a trial, and the prognostic implication of the MGMT methylation status in the same unselected population. Methods: From March 2002 to December 2005 89 pts were reviewed from 8 centers. A Kaplan Meier method and a multivariate analysis (MA) using the Cox model were performed to study the time to progression (TTP) and OS. DNA was available from paraffin in 71 samples. DNA was modified with bisulfit, and methylation specific PCR (MSP) was performed. MGMT promoter methylation status was assessed in 62 (69%) pts. Results: Median age 57 years(y) (18–80). 61,8% males. Complete resection (CR) in 33,7%...